Clinical Question

In children presenting with acute severe asthma, does intravenous aminophylline improve meaningful clinical outcomes compared to standard therapy?

⸻

Background

IV aminophylline has historically been used as a second-line infusion in severe paediatric asthma. However, contemporary escalation strategies increasingly prioritise:

• Oxygen

• High-dose nebulised salbutamol

• Systemic corticosteroids

• IV magnesium sulphate

This raises the question: does aminophylline still offer incremental benefit?

⸻

The Evidence Reviewed

A systematic review published in Archives of Disease in Childhood analysed:

• 9 randomised controlled trials

• 466 children

• Standard therapy ± IV aminophylline

Outcomes assessed:

• Asthma severity scores

• Length of stay

• Admission rates

• PICU admission

• Intubation rates

• Adverse effects

⸻

Key Findings

No significant benefit in:

• Speed of clinical improvement

• Admission rates

• PICU transfer

• Intubation rates

• Length of hospital stay

Significant increase in adverse effects:

• Nausea and vomiting (3–5x higher)

• Headache

• Tremor

• Irritability

• Arrhythmias

Overall: No improvement in meaningful outcomes, with increased morbidity.

⸻

Important Caveat

A 1998 study (Young & South) suggested possible benefit in the most critically unwell, treatment-refractory children, including:

• Reduced duration of intubation

• Potential improvement in lung function

This suggests a potential narrow rescue-therapy window.

⸻

Implications for Paediatric Emergency Practice (2025)

Current best evidence supports:

1. Oxygen

2. Nebulised salbutamol

3. Systemic corticosteroids

4. IV magnesium

5. Structured escalation planning

IV aminophylline should be considered:

• A rescue therapy of last resort

• Not routine second-line treatment

⸻

Take-Home Message

IV aminophylline has historical presence but limited modern evidence of benefit. For most children with acute severe asthma, it increases adverse effects without improving outcomes.

Its role in 2025: rare, selective, and critically contextual.